Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01849263 · ClinicalTrials.gov registry record · Phase 2
Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma
A Phase 2 study of Recurrent Grade 1 Follicular Lymphoma and Recurrent Grade 2 Follicular Lymphoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 13
- Study locations
NCT01849263 is a Phase 2 study of Recurrent Grade 1 Follicular Lymphoma and Recurrent Grade 2 Follicular Lymphoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 41 participants, above the 35-participant average among 11 other Recurrent Grade 1 Follicular Lymphoma trials with a reported enrollment target (17% higher). The trial reports 13 study locations across 8 states.
The verdict
NCT01849263, a Phase 2 study of Recurrent Grade 1 Follicular Lymphoma and Recurrent Grade 2 Follicular Lymphoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 13
- Study locations
Study Summary
This phase II trial studies how well ibrutinib works in treating patients with follicular lymphoma that has come back after a period of improvement or does not respond to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Ibrutinib
Study Locations (13)
Minnesota
- Mayo Clinic in Rochester - Rochester
- Metro Minnesota Community Oncology Research Consortium - Saint Louis Park
- Park Nicollet Clinic - Saint Louis Park - Saint Louis Park
Ontario
- Juravinski Cancer Centre at Hamilton Health Sciences - Hamilton
- Kingston Health Sciences Centre - Kingston
- University Health Network-Princess Margaret Hospital - Toronto
Other
- National University Hospital Singapore - Singapore
- National Cancer Centre Singapore - Singapore
Arizona
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Missouri
- Washington University School of Medicine - St Louis
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Wisconsin
- University of Wisconsin Carbone Cancer Center - University Hospital - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2013-04-02 |
| Est. Completion | 2026-03-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01849263
The ClinicalTrials.gov registry entry for NCT01849263 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 35-participant average among 11 other Recurrent Grade 1 Follicular Lymphoma trials with a reported enrollment target (17% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Recurrent Grade 1 Follicular Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01849263 reports 13 study locations spanning 8 distinct geographic areas - top geographies include Minnesota, Ontario, Other.
Frequently Asked Questions
What is clinical trial NCT01849263 about?
NCT01849263 is a clinical study titled "Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma". This phase II trial studies how well ibrutinib works in treating patients with follicular lymphoma that has come back after a period of improvement or does not respond to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01849263?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2013-04-02. Estimated completion is 2026-03-19.
What conditions does trial NCT01849263 study?
This clinical trial studies the following conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Refractory Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma.
What interventions are being tested in trial NCT01849263?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT01849263?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01849263 being conducted?
This trial has 13 study locations across Arizona, Florida, Minnesota, Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Grade 1 Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma
RECRUITING · Phase 2
-
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation
COMPLETED · Phase 2
-
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Recurrent Grade 1 Follicular Lymphoma
All registered trials for this condition
Recurrent Grade 2 Follicular Lymphoma
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.